Elixinol Wellness Limited, through its subsidiaries, manufactures and distributes industrial hemp-based nutraceutical, dietary supplements, and skincare products in the Americas, Europe, and Australia.
Elixinol Wellness Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.09|
|52 Week High||AU$0.087|
|52 Week Low||AU$0.36|
|1 Month Change||-14.29%|
|3 Month Change||-25.00%|
|1 Year Change||-40.00%|
|3 Year Change||-94.92%|
|5 Year Change||n/a|
|Change since IPO||-93.79%|
Recent News & Updates
Here's Why We're Watching Elixinol Wellness' (ASX:EXL) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
We're Keeping An Eye On Elixinol Wellness' (ASX:EXL) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
|EXL||AU Personal Products||AU Market|
Return vs Industry: EXL underperformed the Australian Personal Products industry which returned 17% over the past year.
Return vs Market: EXL underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: EXL is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: EXL's weekly volatility has decreased from 15% to 8% over the past year.
About the Company
Elixinol Wellness Limited, through its subsidiaries, manufactures and distributes industrial hemp-based nutraceutical, dietary supplements, and skincare products in the Americas, Europe, and Australia. It distributes hemp-derived cannabidiol products under the Elixinol brand. The company was formerly known as Elixinol Global Limited and changed its name to Elixinol Wellness Limited in May 2021.
Elixinol Wellness Fundamentals Summary
|EXL fundamental statistics|
Is EXL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EXL income statement (TTM)|
|Cost of Revenue||AU$5.72m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.079|
|Net Profit Margin||-209.47%|
How did EXL perform over the long term?See historical performance and comparison
Is Elixinol Wellness undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate EXL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate EXL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: EXL is unprofitable, so we can't compare its PE Ratio to the Global Personal Products industry average.
PE vs Market: EXL is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EXL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EXL is good value based on its PB Ratio (1.1x) compared to the AU Personal Products industry average (2.9x).
How is Elixinol Wellness forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Household industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Elixinol Wellness has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Elixinol Wellness performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EXL is currently unprofitable.
Growing Profit Margin: EXL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EXL is unprofitable, and losses have increased over the past 5 years at a rate of 46.7% per year.
Accelerating Growth: Unable to compare EXL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EXL is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (23%).
Return on Equity
High ROE: EXL has a negative Return on Equity (-99.31%), as it is currently unprofitable.
How is Elixinol Wellness's financial position?
Financial Position Analysis
Short Term Liabilities: EXL's short term assets (A$24.2M) exceed its short term liabilities (A$4.2M).
Long Term Liabilities: EXL's short term assets (A$24.2M) exceed its long term liabilities (A$1.8M).
Debt to Equity History and Analysis
Debt Level: EXL's debt to equity ratio (1%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if EXL's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EXL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: EXL has less than a year of cash runway if free cash flow continues to reduce at historical rates of 13% each year
What is Elixinol Wellness's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EXL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EXL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EXL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EXL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EXL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Oliver Horn (49 yo)
Mr. Oliver Horn serves Global Chief Executive Officer at Elixinol Wellness Limited (formerly known as Elixinol Global Limited) since 2021 and served as Group Chief Executive Officer since April 21, 2020 un...
CEO Compensation Analysis
Compensation vs Market: Oliver's total compensation ($USD396.93K) is above average for companies of similar size in the Australian market ($USD302.72K).
Compensation vs Earnings: Insufficient data to compare Oliver's compensation with company performance.
Experienced Management: EXL's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
Experienced Board: EXL's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 63.7%.
Elixinol Wellness Limited's employee growth, exchange listings and data sources
- Name: Elixinol Wellness Limited
- Ticker: EXL
- Exchange: ASX
- Founded: 2017
- Industry: Personal Products
- Sector: Household
- Market Cap: AU$28.390m
- Shares outstanding: 315.44m
- Website: https://www.elixinolwellness.com
- Elixinol Wellness Limited
- 680 George Street
- Level 12
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/18 07:03|
|End of Day Share Price||2021/10/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.